

Table S1. Patient demographics and clinical characteristics.

Number of patients, n	1201
Number of rheumatologists, n	410
Age, mean (SD)	48.86 (12.53)
BMI, mean (SD)	26.78 (4.81)
Gender, n (%)	
Male	559 (46.5)
Female	642 (53.5)
When was PsO diagnosed in relation to PsA?^a n (%)	
PsO before PsA	856 (71.3)
PsA before PsO	74 (6.16)
PsA/PsO diagnosed together	203 (16.9)
No diagnosis of PsO	68 (5.66)
BSA (%), n (%)^b	
<3% (Mild)	198 (29.5)
3-10 (Moderate)	262 (39.0)
>10 (Severe)	212 (31.6)
n, included	672
n, missing	529
BSA(%), median (IQR)^b	5.00 (2.0, 18.0)
n, included	672
n, missing	529
PASI, median (IQR)^b	0.00 (0.00, 3.90)
n, included	1023
n, missing	178

^aAs determined by documentation of diagnosis prior to initiation of current treatment for PsA and selected from a pre-defined list.

^bData were not available for all patients.

SD, standard deviation; n, number of patients; BMI, body mass index; PsO, psoriasis; PsA, psoriatic arthritis; BSA, body surface area; PASI, psoriasis area severity index.

Table S2. Patient comorbidities ($\geq 2\%$) documented as present prior to initiation of the current treatment for PsA in patients when stratified according to inclusion in the skin and joint group. All p-values from Fisher's exact test.

Comorbidity, n (%)^a	Overall n=1201	Not Included n=564	Included n=637	p-value
Anxiety	113 (9.4)	29 (5.1)	84 (13.2)	<0.000
Atopic dermatitis	19 (1.6)	4 (0.7)	15 (2.4)	0.0343
Chronic kidney disease (Mild)	21 (1.7)	7 (1.2)	14 (2.2)	0.2709
COPD	28 (2.3)	14 (2.5)	14 (2.2)	0.8487
Depression	104 (8.7)	30 (5.3)	74 (11.6)	0.0001
Diabetes mellitus	81 (6.7)	33 (5.9)	48 (7.5)	0.2517
Fibromyalgia	52 (4.3)	21 (3.7)	31 (4.9)	0.3945
Gastric condition (not Peptic Ulcer or GI perforation)	34 (2.8)	12 (2.1)	22 (3.5)	0.222
Hyperlipidemia	139 (11.6)	65 (11.5)	74 (11.6)	1
Hypertension	230 (19.2)	88 (15.6)	142 (22.3)	0.0033
Obesity	82 (6.8)	35 (6.2)	47 (7.4)	0.4918
Osteoporosis	35 (2.9)	15 (2.7)	20 (3.1)	0.7317
No comorbidities	783 (65.2)	396 (70.2)	387 (60.8)	0.0007

^aAs determined by documentation of diagnosis prior to initiation of current treatment for PsA and selected from a pre-defined list.

Figure S1. Psoriasis area and severity index (PASI; A) and the percentage of body surfaced area (BSA) affected (B) correlations with physician classification of current skin severity. The numbers of included and missing patients out of those with skin status documented (n=1103) are provided for each measure. **p<0.0001 calculated using Spearman's correlation.

